Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Myriam Curet Sells 408 Shares of Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Myriam Curet sold 408 shares of the business’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $589.75, for a total transaction of $240,618.00. Following the sale, the executive vice president now directly owns 353 shares in the company, valued at approximately $208,181.75. This represents a 53.61 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Intuitive Surgical Price Performance

NASDAQ:ISRG opened at $591.65 on Wednesday. The firm has a 50 day simple moving average of $555.91 and a 200-day simple moving average of $515.92. The firm has a market cap of $210.73 billion, a PE ratio of 92.30, a P/E/G ratio of 5.67 and a beta of 1.39. Intuitive Surgical, Inc. has a 1-year low of $364.17 and a 1-year high of $616.00.

Hedge Funds Weigh In On Intuitive Surgical

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in Intuitive Surgical by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 32,212,196 shares of the medical equipment provider’s stock worth $16,813,478,000 after purchasing an additional 360,591 shares during the last quarter. State Street Corp increased its position in Intuitive Surgical by 1.4% during the third quarter. State Street Corp now owns 15,050,121 shares of the medical equipment provider’s stock worth $7,393,673,000 after purchasing an additional 210,363 shares during the last quarter. FMR LLC increased its position in Intuitive Surgical by 8.3% during the third quarter. FMR LLC now owns 10,971,085 shares of the medical equipment provider’s stock worth $5,389,765,000 after purchasing an additional 838,793 shares during the last quarter. Geode Capital Management LLC increased its position in Intuitive Surgical by 1.9% during the third quarter. Geode Capital Management LLC now owns 7,512,925 shares of the medical equipment provider’s stock worth $3,677,194,000 after purchasing an additional 143,440 shares during the last quarter. Finally, Fisher Asset Management LLC increased its position in Intuitive Surgical by 1.8% during the fourth quarter. Fisher Asset Management LLC now owns 4,868,869 shares of the medical equipment provider’s stock worth $2,541,356,000 after purchasing an additional 86,488 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ISRG. Evercore ISI boosted their price objective on shares of Intuitive Surgical from $490.00 to $530.00 in a report on Monday, January 27th. Royal Bank of Canada boosted their price objective on shares of Intuitive Surgical from $611.00 to $641.00 in a report on Monday, January 27th. Wells Fargo & Company boosted their price objective on shares of Intuitive Surgical from $630.00 to $687.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Leerink Partners boosted their price objective on shares of Intuitive Surgical from $490.00 to $548.00 in a report on Monday, January 27th. Finally, Oppenheimer restated a “market perform” rating on shares of Intuitive Surgical in a research report on Friday, October 18th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $613.10.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.